Summary of Study ST000455
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000351. The data can be accessed directly via it's Project DOI: 10.21228/M8PC8X This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
| Study ID | ST000455 |
| Study Title | Utilizing Metabolomics to Understand Novel Anti-Desmoid Tumor Drugs (part II) |
| Study Summary | This pilot study will use broad spectrum metabolomics to study the tumorigenesis process of fibroblasts to desmoids by investigating paired desmoid and fibroblast cell lines, in addition to unaffected fibroblast cells. Additionally, this pilot study will explore the effects of two of the active drugs identified on the desmoid and fibroblast cells. |
| Institute | RTI International |
| Last Name | Mercier |
| First Name | Kelly |
| Address | 3040 E. Cornwallis Road |
| kmercier@rti.org | |
| Phone | 919-541-6396 |
| Submit Date | 2016-08-31 |
| Raw Data Available | Yes |
| Raw Data File Type(s) | 1r |
| Analysis Type Detail | NMR |
| Release Date | 2017-12-06 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Project:
| Project ID: | PR000351 |
| Project DOI: | doi: 10.21228/M8PC8X |
| Project Title: | Utilizing Metabolomics to Understand Novel Anti-Desmoid Tumor Drugs |
| Project Summary: | Desmoid tumors (DT) are locally invasive soft tissue growths with no directed therapies currently. While two genes (β-catenin and adenomatous polyposis coli) have been found in patients who develop desmoids, it is unclear how these mutations and other downstream mechanisms lead to desmoid tumorigenesis. Extensive research has been explored in the molecular biology of desmoids; however, the use of metabolomics to understand the how the low molecular weight complements of cells, tissues, and biological fluids are perturbed by this highly localized disease. Additionally, the Desmoid Collaboration for a Cure has identified 45 active drugs against primary cell lines. It is unclear how these therapies perturb the metabolome, outside the Wnt and notch pathways. |
| Institute: | RTI International |
| Last Name: | Mercier |
| First Name: | Kelly |
| Address: | 3040 E. Cornwallis Road |
| Email: | kmercier@rti.org |
| Phone: | 919-541-6396 |
